Medy-Tox Inc. Logo

Medy-Tox Inc.

Develops and markets botulinum toxins and dermal fillers for global aesthetic & therapeutic use.

086900 | KO

Overview

Corporate Details

ISIN(s):
KR7086900008
LEI:
Country:
South Korea
Address:
충청북도 청원군 오창읍 각리1길 78 (주)메디톡스, 청원군
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Medy-Tox Inc. is a global biopharmaceutical company focused on the research, development, and commercialization of aesthetic and therapeutic products. The company's core portfolio consists of botulinum toxin preparations, including its flagship brands Neuronox®, INNOTOX®, and Coretox®, and a range of hyaluronic acid dermal fillers, such as Neuramis®. A pioneer in the South Korean market, Medy-Tox has established a significant presence in the global botulinum toxin industry, distinguished by its robust R&D pipeline and the development of multiple unique formulations. The company also produces a dermocosmetic line under the NEURADERM brand and operates an extensive global network to market its products worldwide.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-10 00:00
Notice of Dividend Amount
중간(분기)배당을위한주주명부폐쇄(기준일)결정
Korean 5.3 KB
2025-08-26 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.5 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 2.7 MB
2025-08-11 00:00
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
Korean 16.4 KB
2025-07-22 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 18.2 KB
2025-07-16 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 57.4 KB
2025-07-02 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 62.4 KB
2025-05-14 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 2.0 MB
2025-05-12 00:00
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
Korean 16.5 KB
2025-04-09 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.3 KB
2025-03-28 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 24.0 KB
2025-03-25 00:00
Transaction in Own Shares
자기주식취득결과보고서
Korean 28.9 KB
2025-03-20 00:00
Audit Report / Information
감사보고서제출
Korean 26.6 KB
2025-03-20 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 604.4 KB
2025-03-13 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 10.9 KB

Automate Your Workflow. Get a real-time feed of all Medy-Tox Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Medy-Tox Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Medy-Tox Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

AIM ImmunoTech Inc. Logo
Develops immuno-therapeutics for cancers, immune disorders, and viral diseases.
United States of America
AIM
AKANDA CORP. Logo
Cultivates and distributes pharma-quality medical cannabis for patients in legal markets worldwide.
United States of America
AKAN
Akari Therapeutics Plc Logo
A clinical-stage oncology company developing next-gen ADCs for targeted cancer therapy.
United States of America
AKTX
Akebia Therapeutics, Inc. Logo
Developing and commercializing novel, FDA-approved therapeutics for kidney disease.
United States of America
AKBA
Akero Therapeutics, Inc. Logo
A clinical-stage biotech developing therapies for serious metabolic diseases like MASH.
United States of America
AKRO
Alaunos Therapeutics, Inc. Logo
Developing TCR-T cell therapies to treat solid tumors by targeting specific cancer mutations.
United States of America
TCRT
Aldeyra Therapeutics, Inc. Logo
Biotech developing therapies for ocular and systemic immune-mediated inflammation.
United States of America
ALDX
Alector, Inc. Logo
Pioneers immuno-neurology therapies for neurodegenerative diseases like Alzheimer's.
United States of America
ALEC
Aligos Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel oral therapies for liver and viral diseases.
United States of America
ALGS
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark
ALK

Talk to a Data Expert

Have a question? We'll get back to you promptly.